467 related articles for article (PubMed ID: 29739227)
1. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Ding D; Guo G; Liu Y; Zheng L; Jia G; Deng J; Sun R; Wang X; Guo C; Shang Y; Han Y
Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
[TBL] [Abstract][Full Text] [Related]
5. Additional fibrate treatment in UDCA-refractory PBC patients.
Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
[TBL] [Abstract][Full Text] [Related]
6. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
Zhang Y; Li S; He L; Wang F; Chen K; Li J; Liu T; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Xia Y; Zhou Y; Lu J; Guo C
Drug Des Devel Ther; 2015; 9():2757-66. PubMed ID: 26045661
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
Wang L; Sun K; Tian A; Liu Y; Zhang M; Zhou X; Han Y
Minerva Med; 2022 Dec; 113(6):974-982. PubMed ID: 33949176
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate for patients with asymptomatic primary biliary cirrhosis.
Dohmen K; Mizuta T; Nakamuta M; Shimohashi N; Ishibashi H; Yamamoto K
World J Gastroenterol; 2004 Mar; 10(6):894-8. PubMed ID: 15040040
[TBL] [Abstract][Full Text] [Related]
11. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.
Liu Y; Guo G; Zheng L; Sun R; Wang X; Deng J; Jia G; Yang C; Cui L; Guo C; Shang Y; Han Y
Am J Gastroenterol; 2023 Nov; 118(11):1973-1979. PubMed ID: 36892506
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
14. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
15. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
16. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy.
Han XF; Wang QX; Liu Y; You ZR; Bian ZL; Qiu DK; Ma X
J Dig Dis; 2012 Apr; 13(4):219-24. PubMed ID: 22435507
[TBL] [Abstract][Full Text] [Related]
18. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Levy C; Peter JA; Nelson DR; Keach J; Petz J; Cabrera R; Clark V; Firpi RJ; Morelli G; Soldevila-Pico C; Lindor K
Aliment Pharmacol Ther; 2011 Jan; 33(2):235-42. PubMed ID: 21083674
[TBL] [Abstract][Full Text] [Related]
19. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
[TBL] [Abstract][Full Text] [Related]
20. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]